CSL stock trades at EUR 114.24 with AUD 88.5 billion market cap

Published on 10/12/2026 at 13:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSL stock costs EUR 114.24 on October 12, 2026. Market cap is AUD 88.5 billion and the 52-week high is AUD 222.47.

Key points in brief

CSL stock was trading at EUR 114.24 at Lang & Schwarz on October 12, 2026.
CSL had an AUD 88.5 billion market capitalization and a 52-week range of AUD 90.00 to AUD 222.47.
The finance quote showed a minus 24.31 P/E ratio, while average volume stood at 1,285,210 shares.
Markets Insider reported that Morgan Stanley maintained a Buy rating with an AUD 182.00 price target on October 11, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL stock (AU000000CSL8) was trading at EUR 114.24 at Lang & Schwarz on October 12, 2026 at 1:19 p.m. CEST. The quote places the Australian biopharmaceutical group against an AUD 88.5 billion market capitalization and a 52-week range of AUD 90.00 to AUD 222.47.

Quote stays in active trading

The Lang & Schwarz bid was EUR 113.66 and the ask was EUR 114.82 at the same timestamp. The latest finance quote for CSL Limited showed 452,198 shares traded against an average volume of 1,285,210 shares, giving investors a current liquidity reference.

CSL's primary listing is on the Australian Securities Exchange under ticker CSL. The company operates through CSL Behring and CSL Seqirus, with activities spanning plasma-derived therapies, vaccines and specialty medicines.

Range and valuation define the setup

The current euro quote sits alongside a broad Australian-dollar trading range. The 52-week low is AUD 90.00 and the high is AUD 222.47, while the market capitalization is AUD 88.5 billion as of October 12, 2026.

The finance quote showed a P/E ratio of minus 24.31. That figure reflects the reported earnings basis in the market data rather than a forecast valuation, so the range and earnings profile need to be read together rather than as a single signal.

Analyst target and reporting dates

Markets Insider reported on October 11, 2026 that Morgan Stanley maintained a Buy rating on CSL and set an AUD 182.00 price target. The target is stated in Australian dollars and is therefore separate from the euro quote in Germany.

Simply Wall St lists CSL's annual general meeting for October 27, 2026 and the next first-half 2027 results for February 10, 2027. The same source reports fiscal 2026 revenue of USD 15.8 billion, up 1.50 percent from fiscal 2025, alongside a fiscal 2026 net loss of USD 2.58 billion.

Comparison with peers

CSL: P/E minus 24.31, market capitalization AUD 88.5 billion

Becton, Dickinson and Company (NYSE, USD): plus 0.55 percent, P/E 55.35, market capitalization USD 50.6 billion

Takeda Pharmaceutical Company (NYSE, USD): plus 1.13 percent, P/E 52.09, market capitalization USD 59.6 billion

CSL quote and next dates

For investors tracking the German-market indication, the EUR 114.24 price at Lang & Schwarz is the central level for October 12, 2026. The company calendar points to the October 27 annual meeting and the February 10, 2027 first-half results, while the AUD 182.00 Morgan Stanley target provides a separate analyst reference.

The further course of trading is shown by the continuously updated real-time quote of CSL stock.